Emergent BioSolutions Secures $52.7M U.S. Government Contract Modification For ACAM2000 Smallpox And Mpox Vaccine Supply
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions Wins $64.5M U.S. HHS Contract Modification To Supply Botulism Antitoxin BAT Under Existing 10-Year Agreement
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
Emergent BioSolutions Announces Saudi Approval For ACAM2000, Its Smallpox and Mpox Vaccine
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved
Emergent BioSolutions Inc. 2026 Q1 - Results - Earnings Call Presentation
Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary
Emergent Biosolutions Q1 Earnings Call Highlights
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic ...
Emergent BioSolutions (NYSE:EBS) Surges After Q1 Earnings Beat and Raised Profit Outlook
Emergent BioSolutions Reports First Quarter 2026 Financial Results
Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript
Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est
Emergent BioSolutions Affirms FY2026 Sales Guidance of $720.000M-$760.000M vs $735.000M Est
Emergent BioSolutions Q1 Adj. EPS $0.21 Beats $(0.25) Estimate, Sales $156.100M Beat $145.000M Estimate
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.